BR112019006428A2 - sal de metformina do elafibranor e composição compreendendo um princípio ativo por incluir um sal de metformina do elafibranor - Google Patents
sal de metformina do elafibranor e composição compreendendo um princípio ativo por incluir um sal de metformina do elafibranorInfo
- Publication number
- BR112019006428A2 BR112019006428A2 BR112019006428A BR112019006428A BR112019006428A2 BR 112019006428 A2 BR112019006428 A2 BR 112019006428A2 BR 112019006428 A BR112019006428 A BR 112019006428A BR 112019006428 A BR112019006428 A BR 112019006428A BR 112019006428 A2 BR112019006428 A2 BR 112019006428A2
- Authority
- BR
- Brazil
- Prior art keywords
- elafibranor
- metformin salt
- active ingredient
- composition
- metformin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
- C07C279/24—Y being a hetero atom
- C07C279/26—X and Y being nitrogen atoms, i.e. biguanides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/22—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and doubly-bound oxygen atoms bound to the same carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
a presente invenção se refere aos fármacos derivados do elafibranor. mais especificamente, a invenção se refere a uma composição compreendendo pelo menos um princípio ativo, caracterizada pelo fato de que o pelo menos um princípio ativo inclui um sal de metformina do elafibranor. a presente invenção também se refere à dupla ação do derivado do elafibranor para o tratamento da obesidade associada à esteato-hepatite não alcoólica (nash) e à hipertrigliceridemia.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1659435A FR3056908B1 (fr) | 2016-09-30 | 2016-09-30 | Sel de metformine et d'elafibranor presentant une activite duale pour le traitement de l'obesite associee a la steato-hepatite non alcoolique (nash) et a l'hypertriglyceridemie |
PCT/EP2017/074703 WO2018060373A1 (fr) | 2016-09-30 | 2017-09-28 | Sel de metformine d'elafibranor presentant une activite duale pour le traitement de l'obesite associee a la steato-hepatite non alcoolique (nash) et a l'hypertriglyceridemie |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112019006428A2 true BR112019006428A2 (pt) | 2019-06-25 |
Family
ID=58347453
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112019006428A BR112019006428A2 (pt) | 2016-09-30 | 2017-09-28 | sal de metformina do elafibranor e composição compreendendo um princípio ativo por incluir um sal de metformina do elafibranor |
Country Status (8)
Country | Link |
---|---|
US (1) | US20200023067A1 (pt) |
EP (1) | EP3518912B1 (pt) |
CN (1) | CN110234317A (pt) |
BR (1) | BR112019006428A2 (pt) |
CA (1) | CA3038727A1 (pt) |
FR (1) | FR3056908B1 (pt) |
MX (1) | MX2019003697A (pt) |
WO (1) | WO2018060373A1 (pt) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020115628A1 (en) * | 2018-12-03 | 2020-06-11 | Mankind Pharma Ltd. | Solid forms of elafibranor and process of preparation thereof |
CN110156648A (zh) * | 2019-05-30 | 2019-08-23 | 河北科技大学 | 一种Elafibranor中间体的制备方法 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2774591B1 (fr) * | 1998-02-12 | 2000-05-05 | Lipha | Composition pharmaceutique comprenant l'association metformine et fibrate et son utilisation pour la preparation de medicaments destines a reduire l'hyperglycemie |
FR2841900B1 (fr) | 2002-07-08 | 2007-03-02 | Genfit S A | Nouveaux derives de 1,3-diphenylprop-2-en-1-one substitues, preparation et utilisations |
EP1424070A1 (en) * | 2002-11-28 | 2004-06-02 | Fournier Laboratories Ireland Limited | Combination of a PPAR alpha agonist and metformin for decreasing the serum triglycerides |
TW200906383A (en) * | 2007-08-02 | 2009-02-16 | Handok Pharmaceuticals Co Ltd | Sustained-release formulation comprising metformin acid salt |
CN101531657B (zh) * | 2009-04-23 | 2013-10-16 | 重庆医科大学 | 噻唑烷二酮类药物的二甲双胍盐及其制备方法和用途 |
US9221751B2 (en) | 2009-11-26 | 2015-12-29 | Genfit | Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders |
PT2504005E (pt) * | 2009-11-26 | 2014-01-10 | Genfit | Utilização de derivados de 1,3-difenilprop-2-en-1-ona para tratamento de doenças hepáticas |
MX339374B (es) * | 2011-04-29 | 2016-05-13 | Inst De Investigación En Química Aplic S A De C V | Cocristales ionicos con base en metformina. |
WO2016044433A2 (en) * | 2014-09-16 | 2016-03-24 | Biopharma Works | Metformin derivatives |
AU2016235263A1 (en) * | 2015-03-26 | 2017-10-12 | T3D Therapeutics, Inc. | Methods of treating liver disease using indane acetic acid derivatives |
-
2016
- 2016-09-30 FR FR1659435A patent/FR3056908B1/fr not_active Expired - Fee Related
-
2017
- 2017-09-28 WO PCT/EP2017/074703 patent/WO2018060373A1/fr unknown
- 2017-09-28 CN CN201780073673.1A patent/CN110234317A/zh active Pending
- 2017-09-28 EP EP17781051.2A patent/EP3518912B1/fr active Active
- 2017-09-28 BR BR112019006428A patent/BR112019006428A2/pt not_active Application Discontinuation
- 2017-09-28 CA CA3038727A patent/CA3038727A1/fr not_active Abandoned
- 2017-09-28 US US16/338,189 patent/US20200023067A1/en not_active Abandoned
- 2017-09-28 MX MX2019003697A patent/MX2019003697A/es unknown
Also Published As
Publication number | Publication date |
---|---|
WO2018060373A1 (fr) | 2018-04-05 |
MX2019003697A (es) | 2020-08-13 |
EP3518912A1 (fr) | 2019-08-07 |
US20200023067A1 (en) | 2020-01-23 |
CA3038727A1 (fr) | 2018-04-05 |
EP3518912B1 (fr) | 2020-12-30 |
FR3056908A1 (fr) | 2018-04-06 |
CN110234317A (zh) | 2019-09-13 |
FR3056908B1 (fr) | 2019-04-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201792562A1 (ru) | Глюкагон и коагонисты гпп-1 | |
CL2019000266A1 (es) | Composición de cannabis. | |
BR112018077457A2 (pt) | composição farmacêutica para evitar ou tratar hiperinsulinismo congênito e seu método, hipoglicemia e seu método, síndrome metabólica e seu método e peptídeo isolado | |
BR112018000542A2 (pt) | composições de irna de transtirretina (ttr) e métodos de uso das mesmas para o tratamento ou prevenção de doenças associadas à ttr | |
BR112019007931A2 (pt) | composições antivirais para o tratamento de infecções ligadas ao coronavírus | |
BR112018003984A2 (pt) | anticorpos | |
BR112019012062A2 (pt) | tratamento de uma doença do trato gastrointestinal com um inibidor de jak e dispositivos | |
SV2018005643A (es) | Composiciones de insulina de rapida accion | |
BR112017027567A2 (pt) | proteínas de fusão para inibir a angiogênese | |
CL2018001192A1 (es) | Análogos de saponina triterpeno | |
BR112017011644A2 (pt) | métodos e composições de ativação da ligase parkina | |
CL2016001587A1 (es) | Derivado basado en 1,2-naftoquinona y método de preparación del mismo. | |
BR112019023990A2 (pt) | Bis-octa-hidrofenantreno carboxamidas e conjugados de proteína das mesmas | |
BR112016022593A2 (pt) | composições e métodos para modular a expressão do fator b do complemento | |
BR112018003864A2 (pt) | método para preparação de uma composição de ácido hialurônico, composição, e, método para restauração de um tecido | |
BR112017012381A2 (pt) | imunoterapia para doença angiogênica | |
BR112018013985A2 (pt) | glicosídeos de esteviol altamente solúveis | |
BR112017012406A2 (pt) | formulação com relação fixa de insulina glargina/lixisenatida | |
CO2019002245A2 (es) | Combinación de agonistas de fxr | |
BR112017005272A2 (pt) | uso de cisteamina no tratamento de infecções causadas por leveduras/bolores | |
BR112017014189A2 (pt) | terapia de câncer com um parvovirus combinado com bevacizumabe | |
BR112015016033A2 (pt) | composições e métodos para tratamento de infecções por bactérias | |
BR112017013845A2 (pt) | derivados de glucagon | |
BR112019006428A2 (pt) | sal de metformina do elafibranor e composição compreendendo um princípio ativo por incluir um sal de metformina do elafibranor | |
BR112018004249A2 (pt) | composto, e, composição para prevenção ou tratamento de doenças trombóticas. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] |